{
  "symbol": "PMD",
  "company_name": "Psychemedics",
  "ir_website": "https://investors.psychemedics.com/corporate-profile/default.aspx",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Psychemedics Corporation Reports First Quarter 2024 Financial Results",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Corporation-Reports-First-Quarter-2024-Financial-Results/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Corporation Reports First Quarter 2024 Financial Results\n\nCompany Release -\n\n5/14/2024 4:55 PM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024.\n\nThe Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarter last year.\n\nBrian Hullinger, President, and Chief Executive Officer, stated:\n\n“Although we experienced a decrease in revenues and earnings for the quarter, we remain optimistic about the future. We continue to actively explore new markets and applications for our hair testing solutions. With a renewed focus on client acquisition, we are confident we are positioning the Company first for revenue stabilization and then for growth.”\n\n**About Psychemedics Corporation**\n\nPsychemedics Corporation is the world’s leading provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. To learn more, visit [www.psychemedics.com](http://www.psychemedics.com).\n\n**Use of Forward-Looking Statements**\n\nCautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning future business potential, including revenue stabilization, growth, and new markets and applications for our hair testing solutions, may be “forward looking” statements). Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the changes in U.S. and foreign government regulations, including but not limited to FDA regulations, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission. The forward-looking statements contained herein speak only of the Company's expectations as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based.\n\n**Psychemedics Investor Contact:**\n\nDaniella MehalikVP of Finance (800) 628-8073DaniellaM@psychemedics.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTExNzcyNCM2MjQ5MzY1IzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/MWJjYzU4ODMtNzkzMS00YTgxLWEwZTAtMTI1ZmI1OTYxYjFkLTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Corporation Reports 2023 Financial Results",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Corporation-Reports-2023-Financial-Results/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Corporation Reports 2023 Financial Results\n\nCompany Release -\n\n3/28/2024 8:20 AM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023.\n\n“2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges, my confidence in our potential continues to increase. As cost reductions from Q4 continue to materialize, we will start our pursuit of new markets and new applications for our hair testing science to create value for clients and shareholders,” stated Brian Hullinger, Chief Executive Officer of Psychemedics.\n\n“Leveraging our expertise and reputation for accuracy combined with a renewed focus on client acquisition, we expect that our innovative approach will not only drive sustainable growth but also solidify our position as the leader in the industry,” added Shannon Shoemaker, Chief Revenue Officer.\n\n  * The Company's revenue for the year ended December 31, 2023, was $22.1 million versus $25.2 million for the prior year, a decrease of 12%.\n  * As of December 31, 2023, the Company had cash and cash equivalents of approximately $2.0 million, compared with approximately $4.8 million as of December 31, 2022.\n  * For the fiscal year ended December 31, 2023, the Company reported a net loss of approximately $4.2 million, or $0.72 per share, compared to a net loss of approximately $1.1 million, or $0.19 per share in 2022.\n  * For the fiscal year ended December 31, 2023, total operating expenses were approximately $11.3 million, consisting of approximately $7.2 million in general and administrative, $3.0 million in marketing and selling, and $1.1 million in research and development. This compares with total operating expenses of approximately $10.4 million for 2022, consisting of approximately $5.9 million in general and administrative, $3.2 million in marketing and selling, and $1.3 million in research and development.\n\n\n\n**About Psychemedics Corporation**\n\nPsychemedics Corporation is the world’s leading provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. To learn more, visit [www.psychemedics.com](http://www.psychemedics.com).\n\n**Use of Forward-Looking Statements**\n\nCautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts including but not limited to statements concerning future business potential, growth opportunities, profitability, value, new accounts, new applications and solidifying our position as the leader in the industry, may be “forward-looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the changes in U.S. and foreign government regulations, including but not limited to FDA regulations, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission. The forward-looking statements contained herein speak only of the Company's expectations as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based.\n\n**Psychemedics Investor Contact:**\n\nDaniella MehalikVP of Finance(412) 816-5590DaniellaM@psychemedics.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTA4MDg5MSM2MTc0ODAyIzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/MGEyZjBiNDgtNDAzMy00OWU4LTljM2MtNjk4MDJkMGI0YmEzLTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Recognized-as-a-Top-10-Employee-Health-Testing-Services-Provider/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider\n\nCompany Release -\n\n3/21/2024 9:00 AM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing.\n\nManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee health testing. Psychemedics was selected for its exceptional performance, industry leadership, and dedication to delivering reliable and accurate testing services.\n\n“We are honored to be recognized as one of the Top 10 Employee Health Testing Services Providers,” said Brian Hullinger, Chief Executive Officer and President of Psychemedics Corporation. “This achievement is a testament to our unwavering commitment to providing high-quality, innovative solutions for drug testing.”\n\nPsychemedics’ patented hair analysis technology offers a non-invasive and highly accurate method for detecting drug use over an extended period, providing employers with valuable insights into their employees’ health and well-being. With over 30 years of experience, Psychemedics has helped thousands of companies worldwide maintain safe and drug-free workplaces.\n\nFor more information about Psychemedics Corporation and its innovative hair testing solutions, please visit[ https://www.psychemedics.com](https://www.globenewswire.com/Tracker?data=b_V4RQ6E7uK8J2IricV2uoFBftqfsrqpslSeASos7LmI3brN-VRg_1rNo3nNIlM7q_Q5yzEc5GPej-VWYc_tsCL-5owVjOcJu0AXiSnD6-vNqT7nwYwhY66wHPbJ4vgq).\n\n**About Psychemedics**\n\nPsychemedics Corporation (NASDAQ: PMD) is a leading global provider of innovative hair testing for drugs of abuse. With over 30 years of experience, Psychemedics has pioneered the science of hair testing and provides clients with the most accurate and reliable hair drug test results in the industry. The company's patented technology is used by thousands of companies worldwide to screen applicants and employees for drug use, helping to create safer and more productive workplaces.\n\n**Investor Relations:** Phone: 978-206-8220Email: [InvestorRelations@psychemedics.com](https://www.globenewswire.com/Tracker?data=-RnQItAcxrDxVEqQ7EKD1KTzQjQPDQAbWE7Aa8oplop6J0QXZANP5yABToRXulZilzHg2rApT3TUa8jdl8oHUuSOf0epttRch-CIVoCL7XXb9mXRZCVGil0MWE_wCDASQnnroNr3_O4prwdS4qWYFw==)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTA2NjA1MCM2MTQyOTg3IzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/ZGQwN2IxNTMtZjIyMi00MDYxLTk0MTktMjdjMTZhNGJiMTE2LTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Corporation-Reminds-Stockholders-to-Cast-Their-Votes-forUpcoming-Annual-Meeting-of-Stockholders/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders\n\nCompany Release -\n\n11/18/2024 8:00 AM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, reminds its stockholders to vote ahead of the Company’s upcoming annual meeting of stockholders scheduled for November 25, 2024. Each stockholder’s vote is important. The Company’s Board of Directors recommends that stockholders vote \"FOR\" each proposal at the annual meeting.\n\n**Instructions for voting your shares are set forth below**. The record date for the annual meeting is October 8, 2024. If you have previously voted your shares and do not wish to change your vote, you do not need to take any action. If you have already voted or given your proxy and wish to change your vote, you should follow the procedures described below and in the proxy materials previously distributed for the annual meeting. Even if you plan to attend the annual meeting, we urge you to vote by proxy in advance.\n\n  * **_If you hold your shares through a broker or other nominee_** , please follow the instructions that you receive from your broker or other nominee to ensure that your shares are voted. Submitting your proxy will not prevent you from attending the annual meeting.\n  * **_If you are a stockholder of record_** , you may submit your proxy over the Internet, by phone or by mail as described on the proxy card. These voting methods are summarized below: \n    * _By Telephone_. If you do not have your Voting Control Number on hand, you may be able to vote by calling this line toll-free 844-618-1693. If you have your Voting Control Number, call toll-free (866) 586-3113 and following the voting instructions before 10:00 AM ET.\n    * _By Internet_. Access the website located at [www.proxydocs.com/PMD](http://www.proxydocs.com/PMD) and follow the on-screen instructions using your Voting Control Number, before 10:00 AM ET on November 25, 2024.\n    * _By Mail_. Mark your proxy card, and then date, sign and return it in the postage-paid envelope so it is received prior to the annual meeting.\n\n\n\n**If you have any questions about how to vote your shares for the annual meeting, please contact the Company’s proxy solicitor Alliance Advisors LLC at toll-free 844-618-1693**\n\nThe Company strongly encourages all of its stockholders to read the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the \"SEC\") on October 18, 2024 and other proxy materials relating to the annual meeting, which are available free of charge on the SEC's website at [www.sec.gov](http://www.sec.gov).\n\n**About Psychemedics**\n\nPsychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.\n\n**Investor Relations:** Phone: 978-206-8220Email: [InvestorRelations@psychemedics.com](https://www.globenewswire.com/Tracker?data=2KlUeLjg2aTRgOmTbtu35TmlQlB-9Lnr4rq8LCyfaHUaQokeMwjWbAkpi9-JOmsk3gMrmLMP-Lyeb3EtMWHpzNfJE_G-vbhWyfhRFp30IeW27jiBQ__FV0uxkDunMe3Pw0MeG3mikcfacRQUN7wirQ==)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3NTIzMiM2NTg3MjEzIzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/OTUzOWI0MDMtZDA0Mi00YWUyLThmOTItMDJlOTcwN2FjMDI1LTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Corporation Reports Third Quarter 2024 Financial Results",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Corporation-Reports-Third-Quarter-2024-Financial-Results/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Corporation Reports Third Quarter 2024 Financial Results\n\nCompany Release -\n\n11/12/2024 4:05 PM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.\n\nThe Company’s revenue for three months ended September 30, 2024, was $5.2 million versus $5.7 million for three months ended September 30, 2023, a decrease of 9%. Net loss was $0.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.36 per share, for the three months ended September 2024 and 2023, respectively.\n\nThe Company’s revenue for nine months ended September 30, 2024, was $15.3 million versus $17.1 million for nine months ended September 30, 2023, a decrease of 11%. Net loss was $2.1 million, or $0.35 per share, compared to a net loss of $3.2 million, or $0.56 per share, for the nine months ended September 2024 and 2023, respectively.\n\n**About Psychemedics Corporation**\n\nPsychemedics Corporation is the world’s leading provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. To learn more, visit [www.psychemedics.com](http://www.psychemedics.com).\n\n**Psychemedics Investor Contact:**\n\nDaniella MehalikVP of Finance (800) 628-8073DaniellaM@psychemedics.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MjIyOSM2NTc4NDcwIzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/M2IzZGRjYTItYTkyNS00MmM0LWJiMzAtOGM3MGZhYzA4MDM1LTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Corporation Reports Second Quarter 2024 Financial Results",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Corporation-Reports-Second-Quarter-2024-Financial-Results/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Corporation Reports Second Quarter 2024 Financial Results\n\nCompany Release -\n\n8/13/2024 4:05 PM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024.\n\nThe Company’s revenue for three months ended June 30, 2024, was $4.7 million versus $5.5 million for three months ended June 30, 2023, a decrease of 15%. Net loss was $0.8 million, or $0.14 per share, compared to a net loss of $0.7 million, or $0.13 per share, for the three months ended June 2024 and 2023, respectively.\n\nThe Company’s revenue for six months ended June 30, 2024, was $10.1 million versus $11.4 million for six months ended June 30, 2023, a decrease of 12%. Net loss was $1.5 million, or $0.26 per share, compared to a net loss of $1.1 million, or $0.19 per share, for the six months ended June 2024 and 2023, respectively.\n\nBrian Hullinger, President, and Chief Executive Officer, stated:\n\n“Despite the decline in revenue due to continued lower hiring by our clients, we continue to adjust operating costs with no adverse client impact while actively pursuing new markets and applications.”\n\n**About Psychemedics Corporation**\n\nPsychemedics Corporation is the world’s leading provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. To learn more, visit [www.psychemedics.com](http://www.psychemedics.com).\n\n**Use of Forward-Looking Statements**\n\nCautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning future business potential, including revenue stabilization, growth, new markets and applications for our hair testing solutions, and statements about operating costs may be “forward looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the changes in U.S. and foreign government regulations, including but not limited to FDA regulations, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission. The forward-looking statements contained herein speak only of the Company's expectations as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based.\n\n**Psychemedics Investor Contact:**\n\nDaniella MehalikVP of Finance(800) 628-8073DaniellaM@psychemedics.co\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTIwNDQwNSM2NDIwMTM2IzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/NmY1MDYyMWQtNTAwYS00YTNlLThmOTctZjQ1ZWJkZDA5MTdmLTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Corporation-s-Board-of-Directors-Approves-Plan-to-Terminate-Registration-of-Its-Common-Stock/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n# Index Blank\n\n404\n\nPage not found.\n\n**We're sorry, but the page you have requested is either no longer available, or has been moved.**\n\nPlease try one of the links in the navigation, or if you feel you have reached this page in error, please contact support@q4inc.com for assistance.\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        },
        {
          "title": "Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing",
          "url": "https://investors.psychemedics.com/sec-filings-and-press-releases/news-releases/news-details/2024/Psychemedics-Unveils-Inaugural-Insights-ReportRevealing-Drug-Trends-Through-Hair-Testing/default.aspx",
          "content": "[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [800-522-7424](tel:+8005227424)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[](tel:+8775172033)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[SCHEDULE A TEST](https://www.psychemedics.com/index.php/contact/) [877-517-2033](tel:+8775172033)\n\n[![](//s23.q4cdn.com/712438926/files/images/irw/psychemedics-logo-400px.png)](https://www.psychemedics.com/)\n\n[INVESTORS](/)\n\n[MY ACCOUNT](https://www.drugtestresults.net/)\n\n[](tel:+8775172033)\n\n[](tel:+8775172033)\n\n[ ![Email Alert](//s23.q4cdn.com/712438926/files/images/irw/mail-arrow_inactive_new.png) Email Alert ](/other-information/email-notification/)\n\n[](#)\n\nEntire IR Site  Documents  Press Releases \n\n# Press Release\n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\n![](/files/images/irw/psychlogo.jpg)\n\n#  Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing\n\nCompany Release -\n\n6/21/2024 10:00 AM ET\n\nDownload the PDF version PDF Format (opens in new window)\n\nDALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.\n\nAs pioneers in the field of hair testing, Psychemedics collected hundreds of thousands of hair samples from individuals across diverse industries and regions. Leveraging advanced analytical techniques, the Psychemedics team meticulously analyzed these samples to detect a wide range of drugs and metabolites, forming the foundation of the insights.\n\nThe 2024 Insights Report serves as a testament to the efficacy and advantages of hair testing as the premier method for employment drug screening. It highlights key findings and trends, including:\n\n  * Positive Rate for Drugs Tested: An overall positive rate of 9.5% underscores the significant presence of drug use in the workplace.\n  * Trend Over 5 Years: Over the past five years, our analysis revealed a notable 23% increase in positive drug test rates across various industries.\n  * Marijuana, Cocaine, and Opiates: These substances maintained a notable presence, with marijuana being the most commonly detected.\n  * Rising Trend in Fentanyl: An alarming increase in fentanyl presence over the last couple of years emphasizes the urgency for targeted interventions and testing.\n\n\n\n“In our inaugural report, Psychemedics is proud to unveil a comprehensive analysis of workplace drug use trends,” stated Brian Hullinger, President and Chief Executive Officer at Psychemedics. “As an industry leader in hair testing, Psychemedics remains committed to advancing the field of drug testing and providing innovative solutions to create safer and more productive workplaces.”\n\nThe 2024 Psychemedics Insights Report serves as a vital resource for employers, policymakers, and stakeholders seeking to understand and address the complex challenges posed by drug use in the workforce. To access the full report and learn more about Psychemedics’ pioneering hair testing solutions, visit [https://www.psychemedics.com/wp-content/uploads/2024/06/PMD-2024-Workforce-Insights-Report.pdf](https://www.globenewswire.com/Tracker?data=g2SUY0OvUydsDZtZdLrO4zcFWu139v_my2BoMT4tfctxQGXiux-O3LHnLyTxK5ZcQR7JfvaqUjXFuefkMfjf2FcC1f5lbbR77Z0-vhZIrs8nQPdZpmk_8YiUU_9esTwB5yVXjzx-vcesrSpwVWJHpjLnEyxr8DDDbMUSadZZrm2ElCYW9MaHZ-8H5PmmtBKiMZANrDnDaIWKUI4ZBCdmiu_YWL4mMQER2BsR4Hsy53uxIt11J-tKwfRetvAu1MK9IiozZtaQh9aMJFyxTNJJw50FP1P0GBoS6kgc1kskQd8=).\n\nFor more information about Psychemedics Corporation and its innovative hair testing solutions, please visit[ https://www.psychemedics.com](https://www.globenewswire.com/Tracker?data=Yzp7HUQQMZw7weHG8PRCrk0MEympFchmdfRCDd7wy1i1E5nzL0z4sCb27KbQq3i_gDRMjjADNluL2xlfik0x4JLjeQC4qqqv4er5uAKNAxPNOjjAr7onGCBNn8Kc4E-p).\n\n**About Psychemedics**\n\nPsychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.\n\n**Investor Relations:** Phone: 978-206-8220Email: [InvestorRelations@psychemedics.com](https://www.globenewswire.com/Tracker?data=bQj8XF6pBA5TJcmnjNpMS9vLN9TZB1_wqmgkiqS34KC9gKP9izYSKETxtpF_nnulxgvQocI4dWaLZQL35oNeWwQ_GrVoP2z1hvvUHVgQCmV0maGS6mOcaAnkhq0ZCGzcomJmqiG3RtaWsrT45Z4-nA==)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTE1NjQ5MSM2MzI0ODY4IzIwOTU4OTk=) ![](https://ml.globenewswire.com/media/MTRjOTY3ZGQtODBjMS00NTNlLWI1YjMtMWMzZGQwZWVkNGM2LTExMDc0NzA=/tiny/Psychemedics-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b2b4d705-cbfa-4454-b34d-791c4cc1a95d/small/psychemdicslogo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b2b4d705-cbfa-4454-b34d-791c4cc1a95d)\n\nSource: Psychemedics Corporation \n\n[ View all news ](/sec-filings-and-press-releases/news-releases/)\n\nCopyright 2024, [© Powered By Q4 Inc.](http://q4inc.com/Powered-by-Q4/)\n\n[Menu](javascript:void\\(0\\);) [](#top-of-the-page \"Back to top\")\n"
        }
      ]
    }
  ]
}